Navigation Links
EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
Date:6/18/2009

VIENNA, Austria, and CUXHAVEN, Germany, June 18 /PRNewswire/ -- EUCODIS Bioscience, a company developing, manufacturing, and marketing enzymes and other proteins for the chemical industry, announced today that it has achieved an important milestone in the development of an undisclosed protein for Lohmann Animal Health (LAH), a leading provider of feed components and vaccines for farm animals. This achievement triggered a milestone payment from LAH to EUCODIS Bioscience.

EUCODIS Bioscience is developing an innovative protein that LAH plans to use as the active ingredient of a new product line. EUCODIS Bioscience and LAH currently have two development agreements in place. In February, EUCODIS Bioscience announced the achievement of a development milestone pertaining to a separate agreement with LAH.

"We have made significant progress in developing a protein showing innovative properties that will bring significant value for agricultural applications," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "We are excited about this project, as the product we are developing for our partner LAH has the potential to open a new market in the food and feed industry."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

For more information, please visit http://www.eucodisbioscience.com

About Lohmann Animal Health

Lohmann Animal Health (LAH) is a leading provider of feed components and vaccines for farm animals, contributing to a safe food supply. Based in Germany, LAH is active in major markets worldwide, with more than 70 percent of its revenues generated from export sales. The Company has more than 500 employees in Germany and the United States as well as in its subsidiaries and sales offices in over 30 countries.

As European market leader LAH offers a wide variety of proven and innovative products in the Feed Additives segment. They range from amino acids and antioxidants to flavors and colorants to probiotics and enzymes. LAH also offers the entire spectrum of vitamins and provitamins, including beta-carotene, as well as specialties such as L-carnitine and botanicals.

    For more information, please visithttp://www.lah.de

    Contact Lohmann Animal Health:
    Dr. Roland Boerner
    Head of Corporate Communications
    Lohmann Animal Health GmbH & Co KG
    Heinz-Lohmann-Strasse 4
    D-27472 Cuxhaven
    GERMANY
    +49-4721-747 424
    Roland.Boerner@lah.de

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna
    AUSTRIA
    +43-1-86634-9241
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
   http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 Eurofins Genomics today announced ... College of American Pathologists (CAP) and certification under ... new laboratory in Louisville, KY ... American headquarters. "Our new CLIA-licensed and ... is still considered the ,Gold Standard, method for ...
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" or ... today that it entered into collaboration with Takeda ... the treatment of NASH and other gastrointestinal (GI) ... LUNAR™ and UNA Oligomer chemistry. The financial terms ... commitment to and expertise in GI disorders, we ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration ... to America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy ... country. , Nancy attributes her patriotic nature to her WWII veteran father. She ...
(Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease ... of serious health problems, such as cardiovascular illness, according to research cited in ... Hills Periodontics & Dental Implant Center notes that the correlation between periodontal disease ...
(Date:12/6/2016)... TX (PRWEB) , ... December ... ... in predictive and prescriptive health insights for population health management, announces today ... provider. VitreosHealth will leverage CitiusTech’s cloud-hosted clinical rules engine that offers advanced ...
(Date:12/6/2016)... ON (PRWEB) , ... December 06, 2016 , ... CarriersEdge, ... today announced a new suite of Driver Wellness courses. Offered in three modules, the ... a starting point so fleets can educate drivers about how to stay healthy on ...
Breaking Medicine News(10 mins):